Abbott Park, Ill.
2017 revenues: $8,911,000,000
Fiscal year ending: December 31, 2017
Miles White, chairman & CEO; Hubery Allen, EVP, general counsel & secretary; Brain Blaser, EVP, diagnostic products; John Capek, EVP, ventures; Robert Ford, EVP, medical devices; Stephen Fussell, EVP, human resources; Andrew Lane, EVP, established pharmaceuticals; Daniel Salvadori, EVP, nutritional products; Brian Your, CFO & EVP, finance; Roger Bird, SVP, U.S. nutrition; Sharon Bracken, SVP, rapid diagnostics; Chuck Brynelsen, SVP, Abbott Vascular; Jaime Contreras, SVP, core laboratory diagnostics, commercial operations; Robert Funck, SVP, finance & controller; Elaine Leavenworth, SVP & chief marketing & external affairs officer; Joseph Manning, SVP, international nutrition; Corlis Murray, SVP, quality assurance, regulatory & engineering services; Michael Peterson, SVP, cardiac arrhythmias & heart failure; Sean Shrimpton, SVP, established pharmaceuticals, emerging markets; Jared Watkin, SVP, diabetes care; Alejandro Wellisch, SVP, established pharmaceuticals, Latin America
Abbott followed the blockbuster, $25 billion St. Jude Medical buy with the $5 billion buyout of diagnostics company Alere in early October 2017, but otherwise trod quietly along the M&A trail. Although it took its first-generation Absorb bioresorbable stent off the market, Abbott won FDA approval for its Xience Sierra everolimus-eluting stent. And the bets it placed in the diabetes market proved out as that business grew at a healthy double-digit clip.